Free Trial
NYSEAMERICAN:XTNT

Xtant Medical Q1 2025 Earnings Report

Xtant Medical logo
$0.40 +0.01 (+1.28%)
As of 04:10 PM Eastern

Xtant Medical EPS Results

Actual EPS
N/A
Consensus EPS
-$0.02
Beat/Miss
N/A
One Year Ago EPS
N/A

Xtant Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
$30.65 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Xtant Medical Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Remove Ads

Xtant Medical Earnings Headlines

Xtant Medical price target lowered to $2 from $3 at BTIG
What to do with your collapsing portfolio…
There might be only one way to save your retirement in this volatile time. After watching investors lose $6 trillion in market cap in a matter of DAYS... And after seeing businesses bleeding dry as trade tensions spiral out of control... What the acclaimed “Market Wizard” Larry Benedict — who beat the market by 103% during the 2008 crash — is about to reveal could not only save your retirement from Trump's tariffs…
See More Xtant Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xtant Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xtant Medical and other key companies, straight to your email.

About Xtant Medical

Xtant Medical (NYSEAMERICAN:XTNT) provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana.

View Xtant Medical Profile

More Earnings Resources from MarketBeat